A retrospective cohort study analyzed 280 severe non-proliferative diabetic retinopathy patients (Early Treatment Diabetic Retinopathy Study levels 43–53) receiving combined anti-VEGF (ranibizumab/aflibercept) and laser therapy (2018–2023). Here, VEGFA is linked to proliferative diabetic retinopathy.